Engineered blood has the greatest potential to combat a predicted future shortfall in the US blood supply for transfusion treatments. Engineered blood produced from hematopoietic stem cell (HSC) derived red blood cells in a laboratory is possible, but critical barriers exist to the production of clinically relevant quantities of red blood cells required to create a unit of blood. Erythroblasts have a finite expansion capacity and there are many negative regulatory mechanisms that inhibit in vitro erythropoiesis. In order to overcome these barriers and enable mass production, the expansion capacity of erythroblasts in culture will need to be exponentially improved over the current state of art. This work focused on the hypothesis that genetic engineering of HSC derived erythroblasts can overcome these obstacles.

中文翻译：

---

基因工程体外促红细胞生成。

工程血液具有最大的潜力，可以解决美国输血治疗中预期的未来供不应求的问题。在实验室中由造血干细胞（HSC）衍生的红细胞产生的工程血液是可能的，但是在生产一定数量的血液所需的临床相关数量的红细胞的生产方面存在关键障碍。红细胞具有有限的扩增能力，并且有许多抑制体外红细胞生成的负面调节机制。为了克服这些障碍并实现批量生产，将需要在目前的技术水平上以指数方式提高培养中成红细胞的扩增能力。这项工作侧重于HSC衍生的成红细胞的基因工程可以克服这些障碍的假设。